Hikma Pharmaceuticals PLC
Open
SectorHealthcare
1,476 -0.67
Overview
Share price change
24h
Min
1475
Max
1491
Income | 165M |
|---|---|
Sales | 41M 1.7B |
P/E Sector Avg | 10.771 49.052 |
EPS | 1.07 |
Dividend yield | 5.74 |
Profit margin | 9.698 |
Employees | 9,400 |
EBITDA | 152M 411M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +23.99% upside |
Dividend yield Sector Avg | 5.74% 2.36% |
|---|---|
Next Earnings | 6 Aug 2026 |
Next Ex Dividend date | 13 Aug 2026 |
Market Cap | -526M 3.1B |
|---|---|
Previous open | 1476.67 |
Previous close | 1476 |
News Sentiment
By Acuity
43%
57%
118 / 342 Healthcare
Hikma Pharmaceuticals PLC Chart
Past performance is not a reliable indicator of future results.
About Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.